Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Considerations for Managing Patients With Hematologic Malignancy During the COVID-19 Pandemic: The Seattle Strategy.
Percival MM, Lynch RC, Halpern AB, Shadman M, Cassaday RD, Ujjani C, Shustov A, Tseng YD, Liu C, Pergam S, Libby EN, Scott BL, Smith SD, Green DJ, Gopal AK, Cowan AJ. Percival MM, et al. Among authors: ujjani c. JCO Oncol Pract. 2020 Sep;16(9):571-578. doi: 10.1200/OP.20.00241. Epub 2020 May 5. JCO Oncol Pract. 2020. PMID: 32369409 Free PMC article.
Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience.
Cooper JP, Khajaviyan S, Smith SD, Maloney DG, Shustov AR, Warren EH, Soma LA, Lynch RC, Ujjani C, Till B, Halpern AB, Gopal AK, Deeg HJ, Scott BL, Shadman M. Cooper JP, et al. Among authors: ujjani c. Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):390-395. doi: 10.1016/j.clml.2019.03.003. Epub 2019 Mar 11. Clin Lymphoma Myeloma Leuk. 2019. PMID: 30948330
Impact of Double- or Triple-Hit Pathology on Rates and Durability of Radiation Therapy Response Among Patients With Relapsed or Refractory Large B-Cell Lymphoma.
Kim A, Stevenson P, Cassaday RD, Soma L, Fromm JR, Gopal AK, Smith SD, Till B, Lynch RC, Ujjani C, Shadman M, Warren EH, Menon M, Russell K, Tseng YD. Kim A, et al. Among authors: ujjani c. Pract Radiat Oncol. 2020 Jan-Feb;10(1):44-52. doi: 10.1016/j.prro.2019.09.013. Epub 2019 Oct 1. Pract Radiat Oncol. 2020. PMID: 31585205
The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy.
Ujjani C, Mato A, Hill BT, Allan JN, Lansigan F, Jacobs R, Skarbnik A, Tuncer H, Pagel J, Brander D, Cheson B, Barr P, Roeker LE, Pu J, Shah NN, Goy A, Schuster SJ, Lamanna N, Sehgal A, Tam CS, Shadman M. Ujjani C, et al. Blood Lymphat Cancer. 2020 Aug 24;10:1-5. doi: 10.2147/BLCTT.S262592. eCollection 2020. Blood Lymphat Cancer. 2020. PMID: 32943973 Free PMC article.
Vaccinations in CLL: implications for COVID-19.
Shadman M, Ujjani C. Shadman M, et al. Among authors: ujjani c. Blood. 2021 Jan 14;137(2):144-146. doi: 10.1182/blood.2020009966. Blood. 2021. PMID: 33443562 Free PMC article. No abstract available.
Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials.
Rutherford SC, Yin J, Pederson L, Perez Burbano G, LaPlant B, Shadman M, Li H, LeBlanc ML, Kenkre VP, Hong F, Blum KA, Dockter T, Martin P, Jung SH, Grant B, Rosenbaum C, Ujjani C, Barr PM, Unger JM, Cheson BD, Bartlett NL, Kahl B, Friedberg JW, Mandrekar SJ, Leonard JP. Rutherford SC, et al. Among authors: ujjani c. J Clin Oncol. 2023 Jan 10;41(2):336-342. doi: 10.1200/JCO.21.02301. Epub 2022 Jul 5. J Clin Oncol. 2023. PMID: 35787017 Free PMC article.
75 results